HIGHLIGHTS
- who: Julia Baguña Torres from the The University of Sydney, Australia have published the research: Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration, in the Journal: (JOURNAL)
SUMMARY
Anti-CD20 agent to demonstrate efficacy in relapsing MS, and paved the way for the development of less immunogenic and possibly more potent humanized (ocrelizumab) and fully human (ofatumumab) anti-CD20 mAbs. In randomized phase 3 clinical trials, ocrelizumab (OPERA I and OPERA II) and ofatumumab (ASCLEPIOS I and ASCLEPIOS II) demonstrated superior efficacy to interferon . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.